RESUMEN
The objectives of this study were to quantify the effect of 16 ppm of dietary monensin on milk production and composition of dairy cows, and to investigate factors having a potential impact on this effect. Data were generated from a total of 3577 Holstein dairy cows (47 herds) in Quebec enrolled in a herd-level, randomized clinical trial investigating the effects of monensin supplementation. Milk production and composition data were collected from monthly dairy herd improvement (DHI) testing. Monensin increased milk production by 0.9 kg/cow/d in cows under 150 days in milk (DIM) (P < 0.05). Monensin decreased milk fat percentage by 0.18 percentage points during the whole lactation (P < 0.05). This decreasing effect was larger for component-fed cows (P < 0.05) and for cows being fed low levels of dietary physically effective particles (P < 0.05) when compared respectively to cows fed total mixed ration and cows fed high levels of dietary physically effective particles. The results of this study suggest that monensin influences milk production and milk composition of dairy cows, and that diet composition and feeding system influence those effects.
Asunto(s)
Bovinos/fisiología , Ionóforos/farmacología , Lactancia/efectos de los fármacos , Leche/química , Leche/metabolismo , Monensina/farmacología , Animales , Industria Lechera , Suplementos Dietéticos , Femenino , Ionóforos/administración & dosificación , Lactancia/fisiología , Lípidos/análisis , Leche/efectos de los fármacos , Monensina/administración & dosificación , Tamaño de la Partícula , Quebec , Distribución AleatoriaRESUMEN
Our objective was to define the role of monensin sodium in protecting cows from being milk-ELISA positive for paratuberculosis in Ontario, Canada dairy herds. In total, 4933 dairy cows from 94 herds were enrolled in this cross-sectional study. Forty-four of the enrolled herds were selected purposively by their herd veterinarian and another 50 herds were randomly selected from a local milk production-recording agency. A herd-management survey was completed on each farm during the months of May through August 2003. During this same time-period, composite milk samples were collected from all lactating cows and tested with a milk-ELISA for antibodies to Mycobacterium avium subspecies paratuberculosis. Analyses were stratified according to the paratuberculosis history of the herds. In the 48 herds in which paratuberculosis had not been diagnosed before, the use of calf hutches and monensin in milking cows were both associated with reduced odds of a cow testing positive (OR=0.19 and 0.21, respectively). In the 46 herds with a prior history of paratuberculosis, feeding monensin to the breeding-age heifers was associated with decreased odds of a cow testing positive (OR=0.54). Monensin use might be associated with milk-ELISA positivity, but its impact on the transmission of paratuberculosis remains unknown.
Asunto(s)
Anticuerpos Antibacterianos/análisis , Enfermedades de los Bovinos/diagnóstico , Leche/inmunología , Monensina/farmacología , Mycobacterium avium subsp. paratuberculosis/inmunología , Paratuberculosis/diagnóstico , Animales , Anticuerpos Antibacterianos/efectos de los fármacos , Bovinos , Enfermedades de los Bovinos/prevención & control , Enfermedades de los Bovinos/transmisión , Estudios Transversales , Ensayo de Inmunoadsorción Enzimática/métodos , Ensayo de Inmunoadsorción Enzimática/veterinaria , Femenino , Leche/microbiología , Oportunidad Relativa , Ontario , Paratuberculosis/prevención & control , Paratuberculosis/transmisiónRESUMEN
Reducing the quantity of Mycobacterium avium subsp. paratuberculosis (MAP) being shed by cows with Johne's disease should decrease the risk of spread of this disease to young stock. Previous work has suggested that monensin sodium decreases the pathologic lesions associated with Johne's disease, but the impact on shedding of viable MAP remains unknown. After serologic screening of 32 dairy herds in southwestern Ontario, 228 cows from 13 of these herds were enrolled into a randomized clinical trial. Fecal culture and PCR were used to identify 114 cows as potential fecal shedders, while another 114 cows were enrolled as ELISA negative, herd and parity matched controls. All cows were randomized to receive either a monensin controlled release capsule (CRC) or a placebo capsule. Serial fecal and blood samples were collected for fecal culture and serum ELISA testing over a 98-day period. On day 98 of the study, treatments were switched for all cows continuing in the trial. These remaining cows were followed for another 98 days with a similar sampling protocol. Mixed effect models were used to measure the impact of treatment on the number of colony forming units identified on fecal cultures over time. During the first 98 days of the study, cows treated with a monensin CRC were found to shed 3.4cfu per tube less than placebo treated cows (P=0.05). The serum ELISA S/P ratio was reduced by 1.39 units in cows given monensin (P=0.06). However, treatment with monensin did not reduce the odds of testing positive on serology. Only the cows shedding MAP on day 0 were found to have a reduced odds of testing positive on fecal culture when treated with monensin (OR=0.27; P=0.03). Monensin sodium administered to infected animals at 335mg/day marginally reduced fecal shedding of MAP in mature dairy cattle, but the biological significance of this reduction is unknown.